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BEYOND NATURE? GENOMIC 
MODIFICATION AND THE FUTURE OF 
HUMANITY 
JULIA D. MAHONEY AND GIL SIEGAL* 
“Consider the work of God: For who can make straight that which He hath 
made crooked?” 
–Ecclesiastes 7:13 
I 
INTRODUCTION 
Just as humans dreamed of flying1 long before the Wright Brothers’ maiden 
flight near Kitty Hawk in 1903,2 visions of altering humanity predate recent leaps 
in human genome editing technologies. These methods—most notably 
“CRISPR”3—may make possible things that were once the sole province of 
fiction.4 But in contrast to the early twentieth century rush to exploit 
breakthroughs in human powered and controlled aviation, the modern-day 
reaction to heritable human genome editing is one of hesitation and fear. A 
robust consensus prevails among expert scientists, physicians, legal experts and 
ethicists that we should go forward slowly—if at all—with modifying the human 
genome in ways that promise to extend to future generations.5 Leading press 
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 1.  See, e.g., LEONARDO DA VINCI, NOTEBOOKS 98–101 (Thereza Wells ed., 2008) (depicting flying 
machines modeled on the physiologies of bats and birds).  
 2.  DAVID MCCULLOUGH, THE WRIGHT BROTHERS 85–108 (2015). 
 3.  “CRISPR” stands for “Clustered Regularly Interspaced Short Palindromic Repeats.” A game 
changing development, CRISPR has been called the “Model T of genetics.” Michael Specter, The Gene 
Hackers, NEW YORKER (Nov. 16, 2016), https://www.newyorker.com/magazine/2015/11/16/the-gene-
hackers [https://perma.cc/S7C7-HHQ8] (quoting Stanford University professor Henry T. Greely). See 
infra Part II.  
 4.  See Brendan P. Foht, Gene Editing: New Technology, Old Moral Questions, NEW ATLANTIS, 
Winter 2016, at 3, 3 (“The fears and the hopes of genetically engineering the human race have been 
haunting the modern mind for the better part of a century, although only in the last decade have 
techniques been developed that might give us the power to modify the genomes of human beings at the 
embryonic stage.”).  
 5.  See, e.g., NAT’L ACADS. SCIS., ENG’G & MED., HUMAN GENOME EDITING: SCIENCE, ETHICS, 
AND GOVERNANCE 134 (2017) (“More research is needed before any germline intervention could meet 
the risk/benefit standard for authorizing [human] clinical trials”); Ethical Embryo Editing, 549 NATURE 
307, 307 (2017) (noting that “[c]onsensus guidelines” promulgated by prominent advisory groups hold 
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outlets concur.6 
The need for extreme caution on human germline modification7 is defended 
on a number of grounds: the interests of future generations, safety considerations, 
equality concerns, the evils of eugenics, and the importance of public trust in 
science.8 But none of these justifications bears up under scrutiny. Indeed, what is 
most striking about the case made for proceeding at a crawl—with selected 
research permitted but clinical applications on hold—is how the considerations 
cited in its favor militate instead for advancing with all deliberate speed. 
There is another problem with the “go very slow” approach—namely, that 
events are overtaking it. The simplicity and low cost of some gene editing 
techniques may enable scientists and others to evade legal limits and ethical 
guidelines,9 in effect engaging in what this article terms “genomic 
 
“that editing the human germ line can be justified for the scientific purpose of research into fundamental 
biology” but not yet for “clinical applications”); David Baltimore et al., A Prudent Path Forward for 
Genomic Engineering and Germline Gene Modification, 348 SCIENCE 36, 37 (2015) (cautioning against 
“attempts at germline genomic modifications for clinical applications in humans”); Edward Lanphier et 
al., Don’t Edit the Human Germ Line, 519 NATURE 410, 410 (2015) (“At this early stage, scientists should 
agree not to modify the DNA of human reproductive cells.”). See also Kelly E. Ormond, et al., Human 
Germline Genome Editing: American Society of Human Genetics Position Statement, 101 AM. J. HUM. 
GENETICS 167, 172–73 (2017) (concluding “at this time, given the nature and number of unanswered 
scientific, ethical, and policy questions, it is inappropriate to perform germline gene editing that 
culminates in human pregnancy” and that “[f]uture clinical application of human germline genome 
editing should not proceed unless, at a minimum, there is (a) a compelling medical rationale, (b) an 
evidence base that supports its clinical use, (c) an ethical justification, and (d) a transparent public process 
to solicit and incorporate stakeholder input”); UNESCO INT’L BIOETHICS COMMITTEE, UPDATING ITS 
REFLECTION ON THE HUMAN GENOME AND HUMAN RIGHTS (Oct. 2, 2015), http://unesdoc.unesco.org/ 
images/0023/002332/233258E.pdf [https://perma.cc/DTA5-6Y7X] (endorsing a moratorium on human 
germline editing).  
 6.  E.g., The Age of the Red Pen, THE ECONOMIST (Aug. 22, 2015), 
https://www.economist.com/news/briefing/21661799-it-now-easy-edit-genomes-plants-animals-and-
humans-age-red-pen [https://perma.cc/8LWU-HUFM] (stating that “germline editing is widely seen as a 
bourn no ethical traveler should cross”); A Pause to Weigh Risks of Gene Editing, N.Y. TIMES (Dec. 18, 
2015), https://www.nytimes.com/2015/12/18/opinion/a-pause-to-weigh-risks-of-gene-editing.html [https:// 
perma.cc/RE92-NM5V] (opining that the “technology for altering defects in the human genome has 
progressed so rapidly in the last three years that it has outstripped the ability of scientists and ethicists to 
understand and cope with the consequences” and endorsing a “pause in using the technique to produce 
genetic changes that could be inherited by future generations” until a large number of conditions are 
met).  
 7.  This article uses the terms “heritable human genome editing,” “human germline editing,” and 
“human germline modification” to denote clinical applications of methods designed to alter human 
germline (that is, reproductive) cells, including ova, sperm, the cells that give rise to ova and sperm, and 
very early-stage human embryos. Changes to germline cells have the potential to affect descendants of 
treated individuals. NAT’L ACADS. SCIS., ENG’G & MED., supra note 5, at 3. In this key respect, heritable 
genome editing differs from somatic—or non-inheritable—genome editing, which alters the somatic cells 
that contribute to the various tissues of the body (for example, skin, liver, lungs, heart) but not to the 
germline. The effects of modifications to somatic cells are limited to the individual treated and will “not 
be inherited by future generations.” Id. at 83. Somatic genome editing generally enjoys acceptance for 
interventions aimed at curing or preventing disease or disability. Id. at 103–10. See also infra Part II.  
 8.  See infra Part III. 
 9.  See Niklaus H. Evitt, Shamik Mascharak & Russ B. Altman, Human Germline CRISPR-CAS 
Modification: Toward a Regulatory Framework, 15 AM. J. BIOETHICS 25, 26 (2015) (“A complete ban or 
temporary moratorium will be nearly impossible to enforce due to the low cost of CRISPR and 
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moonshining.”10 As a result, efforts to constrain the spread of human germline 
modification may not only fail to achieve their core aim but drive cutting edge 
work into the shadows—out of sight of government regulators, trusted medical 
and scientific organizations, and the general public. The end consequence could 
be a world in which important biomedical innovation takes place without the 
benefits of inclusive public deliberation.11 
This article is organized as follows. Part II describes the promise of heritable 
genome editing methods and the recent scientific advances that lend urgency to 
questions regarding when, where, how, by whom, and for what purposes these 
new technologies will be deployed. Part III examines the dominant views that the 
best course of action is to “exercise great caution”12 or even “hit the pause 
button”13 when it comes to clinical uses of heritable genome editing technologies. 
In this Part we argue that such recommendations are rooted in flawed 
assumptions, including ones about how the current generation can best safeguard 
and promote the interests of future ones. Although human germline editing 
entails risks, later generations will likely be better served if present day decision 
makers embrace the Enlightenment principles of daring to know14 and harnessing 
knowledge to improve human lives.15 Part IV turns to regulatory and governance 
issues. It explains how all three sectors of the economy—government, nonprofit 
organizations, and profit-seeking firms—play important roles in biomedicine, 
 
heterogeneity of regional ethical codes.”); Debra J. H. Mathews, Robin Lovell-Badge et al., A Path 
Through the Thicket, 527 NATURE 159, 160 (2015) (warning that “the ease of use and accessibility” of 
CRISPR and related technologies “make it ripe for exploitation by rogue or charlatan organizations”); 
Rowan Jacobsen, A Future of Genetically Engineered Children is Closer Than You’d Think, MOTHER 
JONES (September/October 2017), http://www.motherjones.com/politics/2017/08/a-future-of-genetically-
engineered-children-is-closer-than-youd-think/ [https://perma.cc/BM6U-TYHF] (reporting that, even 
though federal law prohibits the Food and Drug Administration (FDA) from “reviewing applications for 
germline editing of human embryos, meaning no clinical trials can move forward,” research in this area 
“continues around the world” and “anyone who wants to escape the rules can do so”). See also infra Part 
II.  
 10.  Not prone to adhere to laws, regulations, or professional norms, the manufacturers of the 
extralegal alcoholic product “moonshine” were particularly active in the United States during the 1920 
to 1933 Prohibition Era. See generally Joseph C. Douglas, Miners and Moonshiners: Historic Industrial 
Uses of Tennessee Caves, 26 MIDCONTINENTAL J. ARCHEOLOGY 251 (2001); Phil Roberts, Regulating 
Liquor: Prohibition Enforcement, Official Corruption, and State Efforts to Control Alcohol after 
Prohibition Repeal, 12 WYO. L. REV. 389 (2012) (describing the response to prohibition laws).  
 11.  Cf. J. BENJAMIN HURLBUT, EXPERIMENTS IN DEMOCRACY: HUMAN EMBRYO RESEARCH 
AND THE POLITICS OF BIOETHICS 2 (2017) (“How should a democratic polity reason together about 
morally and technically complex problems that touch upon the most fundamental dimensions of human 
life—through what institutional mechanisms, guided by what forms of authority, and subject to what 
political norms and limitations?”).  
 12.  Eric S. Lander, Brave New Genome, 373 NEW ENGLAND J. MED. 5, 7 (July 2, 2015). 
 13.  JENNIFER A. DOUDNA & SAMUEL H. STERNBERG, A CRACK IN CREATION: GENE EDITING 
AND THE UNTHINKABLE POWER TO CONTROL EVOLUTION 209 (2017).   
 14.  See Immanuel Kant, What is Enlightenment? (1784), http://www.columbia.edu/acis/ets/ 
CCREAD/etscc/kant.html [https://perma.cc/E7W8-YHK6] (“Dare to know! (Sapere aude.) ‘Have the 
courage to use your own understanding,’ is therefore the motto of the enlightenment.”). 
 15.  See JONATHAN ISRAEL, A REVOLUTION OF THE MIND: RADICAL ENLIGHTENMENT AND THE 
INTELLECTUAL ORIGINS OF MODERN DEMOCRACY 1–20 (2012) (describing the centrality of 
ameliorating the human condition in Enlightenment thought).  
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and offers suggestions for adapting biomedical oversight to present day realities. 
Part IV also details the value of functioning markets for democratic deliberation 
about biomedical innovation. In conclusion, Part V offers some thoughts about 
why human germline modification should attract support from across the political 
spectrum. 
II 
NEW TECHNOLOGIES AND THE HUMAN GENOME 
A. Genome Editing: The Next Weapon in The War on Disease 
Modern medicine has wrought miracles by delivering effective therapies for 
a slew of once untreatable maladies.16 But it still offers far too little to those who 
suffer from—or are carriers of—serious genetic abnormalities. These intractable 
conditions include autosomal recessive disorders such as Tay Sachs disease, a 
neurodegenerative disorder that kills most of its victims in early childhood, and 
sickle cell disease, which causes lifelong problems due to red blood cell 
abnormalities. There are also autosomal dominant conditions, including the late 
onset and always fatal Huntington’s disease. All exact an enormous and ghastly 
toll in terms of physical suffering, emotional distress, and economic loss.17 
To be sure, science and medicine have not ignored the plight of sufferers of 
genetic disorders. For decades, vast quantities of money and expertise have 
poured into gene therapy research and clinical applications.18 Yet while these 
gene therapy initiatives—which entail making changes to somatic, or non-
reproductive cells—have achieved some notable successes,19 progress has proved 
slower and harder than many anticipated.20 
 
 
 16.  See generally ROY PORTER, THE GREATEST BENEFIT TO MANKIND: A MEDICAL HISTORY OF 
HUMANITY (1997). 
 17.  Sheila Jasanoff, J. Benjamin Hurlbut & Krishanu Saha, CRISPR Democracy: Gene Editing and 
the Need for Inclusive Deliberation, 32 ISSUES SCI. & TECH. (Fall 2015), http://issues.org/32-1/crispr-
democracy-gene-editing-and-the-need-for-inclusive-deliberation/ [https://perma.cc/EV8N-6W6J] 
(reporting that “[u]p to 10% of the U.S. population is estimated to carry traits for one or another rare 
genetic disease” and acknowledging that “[o]ur moral intuition rebels against pointless suffering” 
engendered by such conditions). 
 18.  Luigi Naldini, Gene Therapy Returns to Centre Stage, 526 NATURE 351 (2015); James M. Wilson, 
The History and Promise of Gene Therapy, 31 GENETIC ENG’G & BIOTECH. NEWS 62 (2011). 
 19.  E.g., David Benjamin Turitz Cox, Randall Jeffrey Platt & Feng Zhang, Therapeutic Genome 
Editing: Prospects and Challenges, 21 NATURE MED. 121 (Feb. 2015) (describing applications which help 
correct genetic mutations and treat diseases); John Carroll, FDA Experts Offer a Unanimous 
Endorsement for Pioneering Gene Therapy for Blindness, SCIENCE (Oct. 13, 2017), 
http://www.sciencemag.org/news/2017/10/fda-experts-offer-unanimous-endorsement-pioneering-gene-
therapy-blindness [https://perma.cc/Q3Q5-HYHM]. 
 20.  See DOUDNA & STERNBERG, supra note 13, at 158 (cautioning that “[t]he decades-long struggle 
to make good on the promise of gene therapy should serve as a reminder that medical advances are 
almost always more complicated than they might seem”); Maxwell J. Mehlman, Genomics and the Law, 
in THE OXFORD HANDBOOK OF U.S. HEALTH LAW 1113, 1125–26 (I. Glenn Cohen, Allison K. Hoffman 
& William M. Sage eds., 2017) (discussing the history of gene therapy).  
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Somatic genome editing is the obvious next step in this well-established 
approach to developing treatments for genetic conditions21 and as such meets 
with widespread acceptance. But no matter how successful somatic genome 
editing methods turn out to be, the most they can hope to achieve is the cure of 
particular individuals. While that is a great accomplishment, it is not wholly 
satisfactory, for in fighting disease humans seek to do more than prevail in 
individual cases. The history of medicine and public health is one of efforts to win 
wars, not just skirmishes. Victory has meant eradicating scourges such as 
smallpox and polio to save future as well as extant humans from premature death 
and lives marred by disfigurement or paralysis.22 
To end genetic disease is not a matter of vanquishing harmful micro-
organisms. Rather, success will require winning an internal battle of sorts—one 
against aspects of humanity itself. To think along these lines is to ponder a host 
of profound questions that have inspired a rich, voluminous literature in science, 
medicine, philosophy, ethics, and law.23 Until very recently, these questions—
though fascinating—were of more academic than practical interest given that the 
capacity to alter the human germline appeared to be a long way off, if attainable 
at all. While work was ongoing on several promising technologies with potential 
applications for human genome editing,24 no clinical use was on the near or even 
medium-term time horizon. 
This status quo changed in the early years of this decade. Announcement 
followed announcement of startling new developments involving the path 
breaking CRISPR technology, culminating in the harnessing of CRISPR for 
genome editing.25 CRISPR offers nothing less than a “simple, inexpensive, and 
 
 21.  See NAT’L ACADS. SCIS., ENG’G & MED., supra note 5, at 103–09 (noting that in “most respects, 
somatic cell genome editing will be developed with the benefit of gene therapy’s robust base of technical 
knowledge, and within the existing system of regulatory oversight and ethical norms that have facilitated 
the current research and clinical development of somatic cell and gene therapy around the world”). The 
term gene editing denotes “repairs [of] mutated genes directly in the genome, while gene therapy splices 
new, healthy genes into the genome.” DOUDNA & STERNBERG, supra note 13, at 163.  
 22.  PORTER, supra note 16, at 485–87. See also ROBERT WILLIAM FOGEL, THE ESCAPE FROM 
HUNGER AND PREMATURE DEATH, 1700–2100: EUROPE, AMERICA, AND THE THIRD WORLD (2004) 
(describing efforts to increase human longevity).  
 23.  See, e.g., ENGINEERING THE HUMAN GERMLINE: AN EXPLORATION OF THE SCIENCE AND 
ETHICS OF ALTERING THE GENES WE PASS TO OUR CHILDREN (Gregory Stock and John Campbell 
eds., 2000) (describing different perspectives on genomic modification); ALLEN BUCHANAN, DAN W. 
BROCK, NORMAN DANIELS & DANIEL WIKLER, FROM CHANGE TO CHOICE: GENETICS AND JUSTICE 
(2000) (examining ethical issues in genetics within a historical context); JOHN HARRIS, CLONES, GENES, 
AND IMMORTALITY: ETHICS AND THE GENETIC REVOLUTION (1998) (analyzing the moral 
considerations that guide human biotechnology); FRANCES KAMM, MORALITY, MORTALITY: DEATH 
AND WHOM TO SAVE FROM IT (1993) (discussing ethical theories of transplantation and other life-and-
death decisions); PHILIP KITCHER, THE LIVES TO COME: THE GENETIC REVOLUTION AND HUMAN 
POSSIBILITIES (1996) (discussing ethical implications of novel therapies). 
 24.  See, e.g., Thomas Gaj, Charles A. Gersbach, & Carlos F. Barbas, ZFN, TALEN and 
CRISPR/Cas-based Methods for Genome Engineering, 31 TRENDS BIOTECH. 397, 397 (July 2013) 
(describing the Zinc-finger nucleases and transcription activator-like effector nucleases as a “powerful 
class of tools that are redefining the boundaries of biological research”).  
 25.  Patrick D. Hsu, Eric S. Lander & Feng Zhang, Development and Applications of CRISPR-Cas9 
for Genome Engineering, 157 CELL 1262 (2014); CRISPR Timeline, BROAD INSTITUTE, 
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remarkably effective genome engineering method” that enables users to “make 
specific and efficient modifications to a genome.”26 This is important. Although 
advances in DNA sequencing capabilities and the careful study of the genome 
have yielded a plethora of information concerning “the genetic changes that 
influence the development of disease,” the precision tools needed to act on this 
information were lacking.27 CRISPR fills this gap. It was not the first genome 
editing method, any more than the Model T was the first car. But the developers 
of CRISPR—like those of the Model T—succeeded in making “a difficult process 
cheap and reliable.”28 
B. The Pursuit of Knowledge: When Should We Stop? 
The breathtaking speed of advances in CRISPR technology—along with the 
potential dangers of a user-friendly, inexpensive, and portable genome editing 
method—unsettled many, including some of the scientists most closely associated 
with CRISPR research.29 There followed a series of conferences and other 
deliberations on the ramifications of genome editing technologies for science and 
society. One of the highest profile efforts was a January 2015 meeting at the 
Carneros Inn in Napa Valley, inspired in part by the example of the famous 1975 
Asilomar conference on recombinant DNA that led to a research moratorium 
and has become a cynosure of scientific self-regulation.30Attended by prominent 
scientists, bioethicists, and others, the 2015 Napa Valley event generated a 
position statement which was published in the top academic journal Science.31 It 
also helped fuel a 300 plus page report from the National Academies of Sciences, 
Engineering, and Medicine32 as well as statements from UNESCO,33 the 
American Society of Gene and Cell Therapy, the Center for Genetics and 
Society,34 the European Group on Ethics in Science and New Technologies,35 the 
 
https://www.broadinstitute.org/what-broad/areas-focus/project-spotlight/crispr-timeline 
[https://perma.cc/9LBJ-JPLG] (last visited Feb. 18, 2018). 
 26.  Baltimore et al., supra note 5, at 6. 
 27.  Id.  
 28.  Specter, supra note 3. 
 29.  See, e.g., DOUDNA & STERNBERG, supra note 13, at xi–xii, 198–99 (describing how anxieties 
about the misuse and detrimental consequences of her scientific work sparked nightmares for the author).  
 30.  See Paul Berg & Janet E. Mertz, Personal Reflections on the Origins and Emergence of 
Recombinant DNA Technology, 184 GENETICS 9, 15–16 (2010) (recounting—with approval—the 
moratorium on some recombinant DNA experiments imposed as the result of the 1975 conference at 
Asilomar); Henry T. Greely, Of Science, CRISPR-Cas9, and Asilomar, STAN. L. SCH. L. & BIOSCI. BLOG 
(Apr. 4, 2015), https://law.stanford.edu/2015/04/04/of-science-crispr-cas9-and-asilomar/ [https://perma.cc/ 
67DY-RG24]. 
 31.  Baltimore et al., supra note 5. 
 32.  NAT’L ACADS. SCIS., ENG’G & MED., supra note 5.  
 33.  UNESCO INT’L BIOETHICS COMMITTEE, supra note 5.  
 34.  Open Letter Calls for Prohibition on Reproductive Human Germline Modification, CTR. 
GENETICS & SOC’Y (Nov. 11, 2015), https://www.geneticsandsociety.org/internal-content/open-letter-
calls-prohibition-reproductive-human-germline-modification?id=8999 [https://perma.cc/56Q9-MSSL].  
 35.  EUR. GROUP ON ETHICS & SCI. & NEW TECHS. (EGE), STATEMENT ON GENE EDITING 1 
(2016), https://ec.europa.eu/research/ege/pdf/gene_editing_ege_statement.pdf#view=fit&pagemode= 
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Hinxton Group (an international consortium of ethicists, scientists and policy 
experts),36 and many others. While there are important variations in the positions 
articulated—and even a few outliers who push for upping the pace of 
innovation37—the emergent consensus was and remains one of substantial 
caution with respect to human germline editing. Research should continue, albeit 
with careful attention to the fraught ethical issues involved, while clinical 
applications must remain out of bounds so as to provide ample time for 
constructive dialogues among experts and the public about the appropriate uses 
of these new technologies.38 
Implicit in these recommendations is a lack of a sense of urgency.39 The 
unarticulated assumption is that the governments of rich, scientifically advanced 
nations can—and should—act together with leading professional organizations 
to control who will edit the human germline and for what ends. That means they 
have the power to create temporal space for the high quality, unhurried 
deliberations they believe are essential before giving serious consideration to 
allowing medical consumers access to human germline modification. Yet recent 
history and current events both undercut this conception of how things do and 
should work. Every month brings news of more breakthroughs. In July 2017, 
news broke of the “first known attempt at creating genetically modified human 
embryos in the United States.”40 In September 2017, Science reported that 
 
none [https://perma.cc/D9LF-BVEF] (“As to human germline editing, the EGE is of the view that there 
should be a moratorium on gene editing of human embryos or gametes which would result in the 
modification of the human genome.”).  
 36.  Sarah Chan et al., Genome Editing Technologies and Human Germline Genetic Modification: 
The Hinxton Group Consensus Statement, 15 AM. J. BIOETHICS 42 (2015). 
 37.  E.g., John Harris, Germline Manipulation and our Future Worlds, 15 AM. J. BIOETHICS 30 (2015) 
(“We will at some point have to escape beyond both our fragile planet and our fragile nature. One way 
to enhance our capacity to do both these things is by improving on human nature”); Henry I. Miller, 
Letter: Germline Gene Therapy: We’re Ready, 348 SCIENCE 1325, 1325 (Jennifer Sills ed., 2015); Julian 
Savulescu, Jonathan Pugh, Thomas Douglas & Christopher Gyngell, The Moral Imperative to Continue 
Gene Editing Research on Human Embryos, 6 PROTEIN & CELL 476 (2015); Kevin R. Smith, Sarah Chan 
& John Harris, Human Germline Genetic Modification: Scientific and Bioethical Perspectives, 43 
ARCHIVES MED. RES. 491 (2012); Henry I. Miller, Gene Editing is Here, and Desperate Patients Want It, 
WALL ST. J. (Oct. 13, 2017),  https://www.wsj.com/articles/gene-editing-is-here-and-desperate-patients-
want-it-1507847260; Steven Pinker, The Moral Imperative for Bioethics, BOS. GLOBE (Aug. 1, 2015), 
https://www.bostonglobe.com/opinion/2015/07/31/the-moral-imperative-for-bioethics/JmEkoyzlTAu9o 
QV76JrK9N/story.html [https://perma.cc/CQA2-68XK]. 
 38.  E.g., Baltimore et al., supra note 5; EUR. GROUP ON ETHICS & SCI. & NEW TECHS. (EGE), 
supra note 35 (“The EGE considers that deliberation regarding the acceptability and desirability of gene 
editing will require inclusive debate which extends to civil society where diverse perspectives and those 
with different expertise and values can be heard.”).  
 39.  See, e.g., NAT’L ACADS. SCIS., ENG’G & MED., supra note 5, at 189 (“Heritable germline 
genome-editing trails must be approached with caution, but that does not mean they must be 
prohibited. . . . [C]linical trials could be initiated, limited to only the most compelling circumstances and 
subject to a comprehensive oversight framework that would protect the research subjects and their 
descendants; and have sufficient safeguards in place to protect against inappropriate expansion to uses 
that are less compelling or less well understood.”). 
 40.  Steve Connor, First Human Embryos Edited in U.S., MIT TECH. REV. (July 26, 2017),  
https://www.technologyreview.com/s/608350/first-human-embryos-edited-in-us/ [https://perma.cc/2C82-
TX7X] (characterizing the experiment as breaking new ground by demonstrating that it is “possible to 
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scientists in China made effective use of “base editing” (also known as “chemical 
surgery”), a novel and promising embryo editing technique.41 And toward the 
end of 2017, researchers at the Salk Institute announced the development of a 
technique to alter the activity, as distinct from the underlying sequence, of genes 
associated with disease.42 
Perhaps most important, some of the reported breakthroughs involve entities 
not beholden to the policies and value judgments of the establishment organs that 
produce ethical and legal guidelines. The “base editing” breakthrough mentioned 
above was not the first major achievement by this Chinese research team. In fact, 
the New York Times characterized an earlier embryo experiment of theirs as 
“dreaded, yet widely anticipated.”43 This helped fuel the drive—which was 
already well underway—to slow the train of scientific experimentation.44 
The results of the so-called dreaded 2015 experiment were not published in a 
prestigious outlet like Science or Nature, but instead in Protein & Cell—described 
by Science as “an obscure Chinese journal published by an affiliate of China’s 
Ministry of Education.”45 But whether the scientific mainstream likes it or not, 
Protein & Cell’s publication of groundbreaking research findings means it is no 
longer obscure, but internationally known. In sum, the traditional gatekeepers of 
scientific publication have lost a chunk of their power. 
This may not be a bad thing. Many outside of this mainstream world likely 
have their own thoughts on scientific and medical progress and how it should or 
should not go forward.46 It is understandable if they chafe under laws and 
 
safely and efficiently correct defective genes that cause inherited diseases” and noting that while “none 
of the embryos were allowed to develop for more than a few days—and there was never any intention of 
implanting them in a womb—the experiments are a milestone in what may prove to be an inevitable 
journey toward the birth of the first genetically modified humans”). See also Hong Ma et al., Correction 
of a Pathogenic Gene Mutation in Human Embryos, 548 NATURE 413 (2017); Miller, Gene Editing is 
Here, supra note 37 (terming the experiment a “major advance” because, among other reasons, “all of 
the cells in the successfully modified embryos contained the normal DNA” and “if one of the study’s 
corrected embryos had been implanted” there is “a reasonable chance it would have become a healthy 
baby”).  
 41.  Puping Liang et al., Correction of  -thalassemia Mutant by Base Editor in Human Embryos, 8 
PROTEIN & CELL 811 (2017); Jon Cohen, Is a New Embryo-Editing Technique Better than CRISPR?, 
SCIENCE (Sept. 28, 2017),  http://www.sciencemag.org/news/2017/09/new-embryo-editing-technique-
better-crispr [https://perma.cc/48C7-AT3F].  
 42.  Hsin-Kai Liao et al., In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-
epigenetic Modulation, 171 CELL 1495 (2017). 
 43.  Gina Kolata, Chinese Scientists Edit Genes of Human Embryos, N.Y. TIMES (Apr. 24, 2015), 
https://www.nytimes.com/2015/04/24/health/chinese-scientists-edit-genes-of-human-embryos-raising-
concerns.html [https://perma.cc/S9DU-FQG4] (reporting that this experiment had as its objective the 
creation of a non-viable human embryo with “a precisely altered gene in every cell but no other 
inadvertent DNA damage”).  
 44.  See DOUDNA & STERNBERG, supra note 13, at 213–16.  
 45.  Jocelyn Kaiser & Dennis Normille, Chinese Paper on Embryo Engineering Splits Scientific 
Community, SCIENCE (Apr. 24, 2015), http://www.sciencemag.org/news/2015/04/chinese-paper-embryo-
engineering-splits-scientific-community [https://perma.cc/XD7T-MAV9]. There are reports that Nature 
and Science rejected the manuscript “partly because they had ethical objections to the experiments it 
described.” DOUDNA & STERNBERG, supra note 13, at 216.  
 46.  See, e.g., Kaiser & Normille, supra note 45 (describing divergent reactions to reports of embryo 
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guidelines that do not further—and may even be inimical to—their values. 
In a brave new world of inexpensive, easy-to-use technologies,47 this pluralism 
has major ramifications for the design, crafting, and enforcement of legal and 
ethical standards.48 What makes moonshine hazardous, after all, is not that it is 
an alcoholic beverage. It is that making alcohol on the sly often entails methods 
and materials that pose grave risks—both short and long term—to end users. In 
the context of human genome editing, a similar insight holds. The “genomic 
moonshining” that can flow from an insistence on keeping the current bright line 
boundary between somatic and heritable genome editing might have dire side 
effects—ones likely to be most keenly felt by consumers. Before devoting more 
resources to delineating and policing this somatic/heritable boundary, it makes 
sense to take a hard look at it. 
III 
TRANSFORMING HUMANITY: WHY NOT GO FORWARD? 
Deliberations about human genome editing are not taking place against a 
blank backdrop. Article 1 of UNESCO’s 1997 Universal Declaration on the 
Human Genome and Human Rights reads: “The human genome underlies the 
fundamental unity of all members of the human family, as well as the recognition 
of their inherent dignity and diversity. In a symbolic sense, it is the heritage of 
humanity.”49 
From one perspective, statements like this are mere symbolism and provide 
no clear guidance for setting law or policy.50 Formulated at a time when altering 
the human germline was the stuff of fantasy, language about “the heritage of 
humanity” may be better understood as an acknowledgment of the human 
genome’s value as a unique public good than as a move to forestall permanently 
the possibility of any heritable genome modification. But that is not the modal 
interpretation. The principle that the human genome is the “heritage of 
humanity” has for the most part been construed as placing human germline 
modification out of bounds. 
 
 
 
engineering breakthroughs). 
 47.  See Connor, supra note 40 (describing regulatory barriers to the “creation” of “gene-edited” 
individuals in the United States and noting that such creation “could be attempted at any moment” in 
facilities that operate in countries with “no such legal restrictions”).  
 48.  See infra Part IV. 
 49.  UNESCO, UNIVERSAL DECLARATION ON THE HUMAN GENOME AND HUMAN RIGHTS 
(1997), http://www.unesco.org/new/en/social-and-human-sciences/themes/bioethics/human-genome-
and-human-rights/ [https://perma.cc/3MN5-UL6G]. Other prominent institutions have expressed similar 
views. E.g., HUGO ETHICS COMMITTEE, STATEMENT ON BENEFIT-SHARING (Apr. 9, 2000), 
http://www.hugo-international.org/Resources/Documents/CELS_Statement-BenefitSharing_2000.pdf 
[https://perma.cc/G97K-BZTD]. 
 50.  Cf. Pilar N. Ossorio, The Human Genome as Common Heritage: Common Sense or Legal 
Nonsense?, 35 J. L., MED. & ETHICS 425, 425 (2007) (“In the opening years of the 21st century, it became 
fashionable to describe the human genome as belonging to the common heritage of humanity.”).  
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This school of thought has been enshrined in a great deal of law, medicine, 
and scientific practice51—perhaps without careful reflection, but enshrined 
nonetheless. Consequently, as genome editing technologies have emerged, a 
demarcation has been drawn between the probably permissible (somatic genome 
editing, at least for therapeutic goals) and the ethically problematic (heritable 
genome editing).52 
As human germline modification moves from ideation to reality, the question 
of whether to continue to respect this line becomes more pressing. There is no 
convincing argument for doing so, and cordoning off the human germline from 
human interference is a goal that is neither defensible nor likely achievable. In 
what follows, we explain why we reject the rationales for a moratorium on human 
germline modification and instead endorse moving ahead with dispatch. 
A. The Interests of Future Generations 
The most salient distinction between somatic and heritable genome editing is 
that the first affects only the individual treated while the second may affect future 
generations. Opponents of human germline modification argue against moving 
forward on the grounds that later generations may be affected and today’s 
experimenters do not know with certainty what those effects will be.53 
Given the myriad ways the present generation shapes the genetic makeup of 
future generations without a full grasp of the consequences of its actions, this line 
of argument is puzzling. From time immemorial, humans have engaged in mate 
selection with an eye toward the characteristics of their descendants. Increased 
understanding of the human genome has led to the creation of tools for better 
mate choice—in the sense of avoiding grave genetic diseases54—and there is no 
resistance to making thoughtful use of such tools. In addition, antibiotics and 
many other modern medical treatments have the “inadvertent but accepted 
 
 51.  See Elisabeth Hildt, Human Germ Line Interventions—Think First, 7 FRONTIERS GENETICS 81, 
81 (2016) (“Up to now, at least in Western countries, there has been a broad consensus to ban 
interventions that aim to modify the human germline.”); Lander, supra note 12, at 7 (“At least among 
Western governments, there has been a longstanding consensus that manipulating the human germline 
is a line that should not be crossed.”); Francis Collins, Statement on Nat’l Inst. of Health Funding of Research Using 
Gene-Editing Tech.’s in Human Embryos, NAT’L INST. HEALTH (Apr. 28, 2015),  https://www.nih.gov/about-
nih/who-we-are/nih-director/statements/statement-nih-funding-research-using-gene-editing-
technologies-human-embryos [https://perma.cc/F6FE-6NWB] (“The concept of altering the human 
germline in embryos for clinical purposes has been debated over many years from many different 
perspectives, and has been viewed almost universally as a line that should not be crossed.”).  
 52.  Foht, supra note 4, at 5 (“The conventional wisdom that has taken shape around genetic 
technologies holds that we should sharply distinguish between ‘somatic’ gene therapies (which we are 
supposed to consider largely acceptable) and ‘germline’ gene therapies (which we should oppose).”). 
 53.  E.g., Lanphier et al., supra note 5, at 410 (maintaining that “genome editing in human embryos 
using current technologies could have unpredictable effects on future generations. This makes it 
dangerous and ethically unacceptable”).  
 54.  See Barbara Prainsack & Gil Siegal, The Rise of Genetic Couplehood? A Comparative View of 
Premarital Clinical Testing, 1 BIOSOCIETIES 17 (2006) (describing “Dor Yeshorim,” a genetic testing 
program designed to assess the “genetic compatibility of prospective couples in Orthodox Jewish 
communities in Europe, the U.S. and Israel”); Gil Siegal, Looking for Ms. or Mr. Gene Right: Premarital 
Genetic Screening, ACTION BIOSCIENCE (June 2007), http://www.actionbioscience.org/genomics/ 
siegal.html [https://perma.cc/65K6-YUGQ].  
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effects” of “alter[ing] the allele frequency of certain disease-causing mutations in 
the human gene pool”55 by saving patients who would otherwise perish. 
Turning to more controversial practices, reproductive medicine in the United 
States and other countries often entails procedures designed to reduce the 
number of individuals with particular genetic traits. Most prominently, both pre-
implantation genetic diagnosis (PGD)56 and pregnancy termination are widely 
employed to prevent live births of children with genetic problems.57 There is no 
dispute that the present generation’s use of PGD and selective termination 
affects the genetic profiles of future generations. This point bears emphasis, for 
one argument against human germline editing is that it may lead to the 
modification of genes that confer benefits as well as cause harm.58 While this is a 
risk that deserves attention, it is one we are already running. 
The conviction that the welfare of future generations is best served by 
eschewing heritable genome editing may stem from a view that there is “option 
value” in holding back.59 Under that line of thought, editing the human germline 
will lead to irreversible consequences while refraining from doing so now 
preserves an option to do so later.60 But this is not a satisfactory argument. First, 
as noted earlier, human behavior already has a significant impact on the 
genotypes of members of future generations. There is no basis to a claim that 
practitioners are delaying a decision in this area or that their acts remain 
“reversible.” Second, the assumption that scientific progress can be tolled ignores 
what we know about the nature of innovation. Leaps of human understanding of 
the magnitude seen in the past decade are the exception in human history, not 
the rule. And they have often stemmed from active, complex social networks 
comprising universities, conduits of knowledge and highly motivated, talented 
individuals61—exactly the sort of environment that recent accounts of CRISPR’s 
development describe as key to CRISPR’s stunning successes.62 All of this means 
 
 55.  Donald B. Kohn, Matthew H. Porteus & Andrew M. Scharenberg, Ethical and Regulatory 
Aspects of Genome Editing, 127 BLOOD 2553, 2554 (2016). 
 56.  See HENRY T. GREELY, THE END OF SEX AND THE FUTURE OF HUMAN REPRODUCTION 2 
(2016) (predicting that in the next twenty to forty years most well off would-be parents will reproduce by 
having embryos created in a lab and then using PGD to assess the embryos for transfer, with some 
selected for implant but many rejected as suboptimal).  
 57.  The potential of human germline editing to reduce the number of discarded embryos and fetuses 
is one reason the authors believe human germline editing should appeal to many who identify as pro-life. 
See infra Part V. 
 58.  One commonly cited example is the gene for sickle-cell disease, which also confers some 
protection from malaria. See Catherine de Lange, How Sickle Cell Carriers Fend Off Malaria, NEW 
SCIENTIST, (May 11, 2011), https://www.newscientist.com/article/dn20450-how-sickle-cell-carriers-fend-
off-malaria/ [https://perma.cc/UB6C-AZT9] (summarizing research on the “elusive mechanism” of this 
phenomenon).  
 59.  Cf. Julia D. Mahoney, The Illusion of Perpetuity and the Preservation of Privately Owned Lands, 
44 NAT. RES. J. 573 (2004) (examining the “option value” of decisions not to develop land).  
 60.  Cf. AVINASH K. DIXIT & ROBERT S. PINDYCK, INVESTMENT UNDER UNCERTAINTY (2014).  
 61.  See generally JOEL MOKYR, THE GIFTS OF ATHENA: HISTORICAL ORIGINS OF THE 
KNOWLEDGE ECONOMY (2002) (tracing the development of human knowledge). 
 62.  E.g., Eric S. Lander, The Heroes of CRISPR, 164 CELL 18, 18 (2016) (observing that “an 
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hitting the pause button on human germline editing may not be as viable an 
option as its proponents assume. There is no way to put individuals and 
institutions in suspended animation such that, when the resume button is pushed, 
things are bound to pick up where they left off. Broken momentum means lost 
opportunities. 
How the present generation should take account of the needs and preferences 
of future generations raises hard questions with no simple answers.63 “It has 
been,” writes philosopher Annette Baier, “a normal human wish that future 
generations will not curse their predecessors, but rise up and call them blessed.”64 
With that in mind, it is worth pondering the emotions that a decision to call “time 
out” on human germline modification will inspire in the later born. While 
gratitude is a possibility, it is also easy to imagine bewilderment or irritation at 
those who failed to do what they could to combat devastating genetic diseases. 
On the other hand, if history is any guide, a choice to go ahead may well elicit 
admiration and even wonder.65 
B. Safety 
All new medical technologies entail risks. For a sobering reminder of how 
quickly and unexpectedly things can go wrong, one need only look at the history 
of efforts to develop gene therapy treatments.66 In determining whether to move 
ahead with heritable human germline editing, the question at hand is not whether 
it is perfectly safe. It is not.67 But to demand perfect safety would be absurd. When 
 
inspiring ensemble of a dozen or so scientists . . . with their collaborators and other contributors . . . 
discovered the CRISPR system, unraveled its molecular mechanisms, and repurposed it as a powerful 
tool for biological research and biomedicine”). 
 63.  See Julia D. Mahoney, Perpetual Restrictions on Land and the Problem of the Future, 88 VA. L. 
REV. 739 (2002) (examining intergenerational obligations in the context of restrictions on land 
development); Martin L. Weitzman, A Review of The Stern Review on the Economics of Climate Change, 
45 J. ECON. LIT. 686, 690 (2007) (discussing the complexities of taking the welfare of future generations 
into account when crafting climate change policy).  
 64.  Annette Baier, For the Sake of Future Generations, in EARTHBOUND: NEW INTRODUCTORY 
ESSAYS IN ENVIRONMENTAL ETHICS 214, 215 (Tom Regan ed., 1984). 
 65.  Cf. MCCULLOUGH, supra note 2, at 227–29 (describing the celebration of the Wright brothers’ 
flight); MOKYR, supra note 61, at 297 (“Given that increasing this knowledge was costly and often socially 
disruptive, the political will by agents who controlled resources to actually do so . . . was not invariably 
there. . . . [but] useful knowledge mattered. It is neither Whiggish nor naïve to suggest that its accelerating 
growth since 1750 has affected the world more than all other social and political changes taken 
together.”). 
 66.  See Mehlman, supra note 20, at 1125–26 (recounting the death of a nineteen-year old in the 
course of an “experiment to develop a gene transfer treatment for a genetic liver disease with severe and 
often fatal effects on newborns”). 
 67.  See Collins, supra note 51 (citing “serious and unquantifiable safety issues” as a reason why the 
National Institutes of Health “will not fund any use of gene-editing technologies in embryos”); Jennifer 
A. Doudna, Embryo Editing Needs Scrutiny, 528 NATURE S6 (Dec. 2015) (urging scientists to develop 
standards); Stefan Hohmann, Editor’s Comment on “CRIPR/Cas9-mediated Gene Editing in Human 
Zygotes Using Cas9 Protein,” 292 MOD. GENETICS GENOMICS 535, 535 (2017) (expressing the view that 
present and previous work indicate that the safety hurdles in early stage embryo editing can probably be 
overcome while cautioning there is a “long way until gene editing in human embryos becomes feasible 
with high fidelity and safety”). 
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analyzing risks, recall that society does not expect certainty in removing all 
possible harms. Such a demand would make any progress impossible in medicine 
and all other fields. 
Rather, one must ask whether the “heritable” component of genome editing 
is such a reliable proxy for danger that it makes sense to continue to put a heavy 
thumb on the scale for developing somatic genome editing applications while 
stalling heritable ones. Here it is hard to make out a convincing case for “yes.” 
Editing somatic cells to treat genetic disease is “much more complex” as a 
practical matter than editing germ cells68 and carries significant risks of its own.69 
Whether any particular application of genome editing technologies is appropriate 
for use will hinge on the precise facts of particular circumstances. Insisting on a 
bright line between somatic and heritable genome editing, in short, is not a 
reliable means of ensuring safety. This is particularly true given the prospect of 
“genomic moonshining.” Restrictions on heritable genome editing could drive 
consumers who are denied treatment at reputable medical centers to seek help 
from dodgier entities,70 exposing desperate families to serious harms. 
C. Equality 
Some express fears that the use of heritable genome editing will worsen 
societal inequalities and lead to a world of genetic haves and have-nots.71 Upon 
examination, this concern is not persuasive. By far the strongest demand for 
human germline editing will probably be for modifications aimed at eliminating 
devastating heritable conditions. Those efforts will result in greater, not lesser, 
equality as more individuals enjoy lives free from the burdens of serious genetic 
ailments like Tay Sachs disease, Sickle Cell anemia, and Huntington’s disease. In 
short, heritable genome editing has enormous potential to be an equalizing 
technology.72 
 
 
 68.  DOUDNA & STERNBERG, supra note 13, at 160 (“Reversing a disease-causing mutation in a 
single human germ cell is much simpler than trying to do the same thing inside some of the fifty trillion 
somatic cells that make up a human body. To pull that off, scientists have to solve a host of new 
problems.”). 
 69.  See NAT’L ACADS. SCIS., ENG’G & MED., supra note 5, at 88–89.  
 70.  Cf. GLENN COHEN, PATIENTS WITH PASSPORTS: MEDICAL TOURISM, LAW AND ETHICS 
(2014) (detailing the risks associated with medical tourism); R. Alta Charo, On the Road (to a Cure?)—
Stem-Cell Tourism and Lessons for Gene Editing, 374 N. ENG. J. MED. 901, 901 (2016) (“Given the stories 
about amazing potential and early breakthroughs in laboratory and animal models, gene editing may 
trigger another wave of medical tourism.”).  
 71.  E.g., About Human Germline Editing, CTR. GENETICS & SOC’Y (July 9, 2015), 
https://www.geneticsandsociety.org/internal-content/about-human-germline-gene-editing 
[https://perma.cc/4SVV-Q3J4]; Marcy Darnovksy, Human Gene Editing is a Social and Political Matter, 
Not Just a Scientific One, THE GUARDIAN (Dec. 4, 2015), 
https://www.theguardian.com/science/2015/dec/04/ human-gene-editing-is-a-social-and-political-matter-
not-just-a-scientific-one [https://perma.cc/X6QQ-KRFQ]. 
 72.  See PHILIP KITCHER, THE LIVES TO COME: THE GENETIC REVOLUTION AND HUMAN 
POSSIBILITIES 326 (1996) (arguing that the “most exhilarating prospect” of new genetic technologies is 
the ability “to repair misfortunes that ground tragic inequalities in the quality of lives”).  
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Of course, it is possible that there will also be demand for so-called 
enhancements—a difficult to define term that generally “refer[s] to changes that 
alter what is ‘normal,’ whether for humans as a whole or for a particular 
individual prior to enhancement.”73 If that is true, then the gulf between the 
richer and the poorer could grow as some spend money on genetic improvements 
while others go without. There are two points to make about enhancements. 
First, the traits most often mentioned as probable objectives of enhancement 
efforts—intelligence, athletic prowess, and the like—are very complex ones not 
susceptible to being “predicted using DNA tests.”74 As a result, the issue of 
enhancements may never pose much of a quandary. To shrink from helping 
individuals (or families of potential individuals) with serious genetic diseases due 
to speculation that the “one percent” may eventually use human germline editing 
to enhance themselves seems hard to defend. Second, somatic genome editing is 
also a potential vehicle for achieving enhancements.75 That means that opposition 
to enhancements is not a good reason to support a bright line between somatic 
and heritable genome editing. 
D. “Eugenics” 
The most emotionally charged criticism of heritable genome editing is that it 
threatens to usher in a new era of “eugenics.”76 Popular during the first third of 
the twentieth century, the so-called science of eugenics held that excessive 
breeding by the unfit was degrading the quality of the human “stock.” These fears 
led to a surge of involuntary sterilizations around the world, including an 
estimated 60,000 in the United States alone.77 In 1927, the U.S. Supreme Court 
sustained Virginia’s eugenics law against constitutional challenge in Buck v. 
Bell78—a decision now so notorious it is considered part of U.S. constitutional 
law’s “anti-canon.”79 
 
 
 73.  NAT’L ACADS. SCIS., ENG’G & MED., supra note 5, at 138.  
 74.  Cecile J.W. Janssens, Forget About Designer Babies: Gene Editing Won’t Work on Complex 
Traits Like Intelligence, CONVERSATION (Dec. 3, 2015), https://theconversation.com/forget-about-
designer-babies-gene-editing-wont-work-on-complex-traits-like-intelligence-51557 
[https://perma.cc/RQ5K-8JJU]. See also JIM KOZUBEK, MODERN PROMETHEUS: EDITING THE HUMAN 
GENOME WITH CRISPR-CAS9, at 345–55 (2016).  
 75.  See NAT’L ACADS. SCIS., ENG’G & MED., supra note 5, at 147–48.  
 76.  E.g., Robert Pollack, Letter: Eugenics Lurk in the Shadow of CRISPR, 348 SCIENCE 871, 871 
(2016) (asserting that a complete and total ban on human germline modification is warranted to prevent 
the “opening of a return” to practices of eugenics, which entail the “weeding out of the ‘bad’ versions” 
of the human genome “not just for the health of an individual, but for the future of the species”). 
 77.  THOMAS C. LEONARD, ILLIBERAL REFORMERS: RACE, EUGENICS & AMERICAN ECONOMICS 
IN THE PROGRESSIVE ERA (2017); Philip R. Reilly, Eugenics and Involuntary Sterilization: 1907–2015, 
16 ANN. REV. GENOMICS & HUM. GENETICS 351 (2015). 
 78.  274 U.S. 200 (1927).  
 79.  RANDY E. BARNETT & JOSH BLACKMAN, CONSTITUTIONAL LAW: CASES IN CONTEXT 949 
(2017). See also ADAM COHEN: IMBECILES: THE SUPREME COURT, AMERICAN EUGENICS, AND THE 
STERILIZATION OF CARRIE BUCK (2016); PAUL A. LOMBARDO, THREE GENERATIONS, NO 
IMBECILES: EUGENICS, THE SUPREME COURT, AND BUCK V. BELL (2010). 
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What those who invoke the specter of eugenics fail to recognize is that human 
germline modification is its opposite, not its heir. At the core of support for 
eugenics was the conviction that—for the benefit of society—certain individuals 
should not reproduce. The alleged good of the collective trumped the rights of 
individuals, and government force took center stage in determining the genetic 
profile of the generations to come.80 By contrast, a chief goal of heritable genome 
editing would be to expand the options available to individuals while leaving 
sensitive decisions about family life up to them. If this technology fulfills its 
promise, then many with well-founded anxieties about the genetic makeup of 
their descendants who in the past would have hesitated to have children will have 
access to viable treatments. 
E. Public Trust in Science 
Highly sensitive to worries that biomedical technologies might unleash 
terrible ills,81 some scientists and policy experts defend a moratorium on human 
germline editing on the grounds that failure to do so could erode public support 
of CRISPR and other gene editing technologies. They fear that such a loss could 
delay clinical uses of somatic genome editing82 and reduce scientists’ public 
standing.83 
The problem with these arguments is that they amount to little more than 
overwrought speculation. While the evidence on public attitudes toward human 
germline editing is sparse, the results of a just-published survey are instructive. 
Respondents expressed approval of both somatic and germline therapies, with 
roughly two-thirds deeming each “acceptable.”84 These findings may reflect a 
shift in public attitudes.85 But it bears emphasis that even earlier surveys that 
found less support for human germline modification did not report any findings 
indicating that the public is up in arms over it. A 2016 Pew Research Center 
report on public attitudes toward biomedical technologies stressed that “large 
shares” of Americans surveyed “say they think of science and technology, writ 
large, as mostly beneficial forces in American society”86 and found that when 
 
 80.  Daniel Frost, Protection Against Eugenics: A Comparison of Two Jurisprudences, 42 J. SUP. CT. 
HIST. 275, 276–78 (2017).  
 81.  See Specter, supra note 3.  
 82.  See DOUDA & STERNBERG, supra note 13, at 211; Lanphier et al., supra note 5, at 411 .  
 83.  E.g., Niklaus H. Evitt, Shamik Mascharak & Russ B. Altman, Human Germline CRISPR-CAS 
Modification: Toward a Regulatory Framework, 15 AM. J. BIOETHICS 25, 26 (2015) (expressing concern 
that “rapid proliferation” of germline editing therapies could lead to “public mistrust” of the scientists 
developing these new technologies). 
 84.  Dietram A. Scheufele et al., U.S. Attitudes on Genome Editing, 357 SCIENCE 553, 553 (2017).  
 85.  See Jon Cohen, Americans are Becoming More Open to Human Genome Editing, Survey Finds, 
but Concerns Remain, SCIENCE (Aug. 10, 2017), http://www.sciencemag.org/news/2017/08/americans-
are-becoming-more-open-human-genome-editing-survey-finds-concerns-remain 
[https://perma.cc/6T9C-X3NU].  
 86.  Cary Funk, Brian Kennedy& Elizabeth Sciupac, U.S. Public Wary of Biomedical Technologies 
to “Enhance” Human Abilities, PEW RES. CTR. 97 (2016), http://assets.pewresearch.org/wp-
content/uploads/sites/14/2016/07/02120148/PS_2016.07.26_Human-Enhancement-Survey_FINAL.pdf 
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asked about heritable “changes to a baby’s genetic makeup,” roughly half 
reported feeling “very” or “somewhat” enthusiastic about the technology.87 
Given these findings, one can argue that skittish scientists and others should 
focus on how refusing to proceed with promising avenues of inquiry could 
undermine public confidence in science and technology. In catering to fears not 
firmly grounded in reality, they risk looking more like purveyors of moral panics 
or politicians manqué than dispassionate, trustworthy seekers of truth. 
F. Conclusion 
The arguments mustered against proceeding with heritable genome 
modification are not persuasive. While opponents raise serious concerns, all point 
against calling time out on the development of clinical applications of human 
germline editing. Admittedly, predictions are hard, especially about the future,88 
and this is an area of unusual dynamism. Nevertheless, it is not just possible but 
essential to reach a preliminary conclusion about whether to go forward or sit 
tight. 
Throughout history, biomedical advances have tended to improve rather than 
degrade human well-being. These measures have (often inadvertently) altered 
the genetic makeup of future generations. While both somatic and heritable 
genome editing pose dangers that should command attention, there is no 
justification for labeling somatic interventions necessarily safer than germline 
ones. In addition, on balance human germline editing appears more likely to 
reduce—rather than fuel—health inequalities as it will likely lead to the births of 
fewer humans with serious genetic diseases. As for the alleged hazard of eugenics, 
the rise of human germline editing promises to undermine, not increase, 
government power over what genes will and will not be passed down to later 
generations. Finally, it is hard to think of a faster way to erode public trust in 
science and scientists than to invoke unsound reasons to put a stop to efforts to 
prevent, treat, and cure serious diseases. 
IV 
THE REGULATION OF GENOME EDITING TECHNOLOGIES: 
THE STATE, NONPROFIT ORGANIZATIONS AND THE MARKET 
A decade ago, human germline modification lay far in the future, and some 
 
[https://perma.cc/DW6K-X49K].  
 87.  Id. at 122–23. Those surveyed were provided with this vignette: 
New developments in genetics and gene-editing techniques are making it possible to treat some diseases 
and conditions by modifying a person’s genes. In the future, gene-editing techniques could be used for 
any newborn, by changing the DNA of the embryo before it is born, and giving that baby a much reduced 
risk of serious diseases and conditions over his or her lifetime. Any changes to a baby’s genetic make-up 
could be passed on to future generations if they later have children, and over the long term this could 
change the genetic characteristics of the population.  
 88.  This statement is often attributed to Niels Bohr. See Alan G. Mencher, On the Social 
Deployment of Science, 27 BULL. ATOMIC SCIENTISTS 37 (1971). Yogi Berra, Sam Goldwyn and others 
are also credited with variations of it. 
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doubted it would come at all. Even with the advent of CRISPR, there seemed to 
be ample time to ponder at leisure the consequences of a technology that 
although having the “potential to free humanity from painful diseases” might, or 
so many fear, take society to “creepy places.”89 But events are moving faster than 
expected. As cutting-edge research in this area attracts interest around the world, 
it appears increasingly likely that the United States and other powerful 
governments will not be able to halt human germline modification—even if they 
want to do so.90 That makes the need to consider how best to proceed with 
“editing humanity” ever more pressing.91 
Not surprisingly, legal issues relating to human germline modification are 
receiving worldwide attention.92 As of 2018, however, there is no discernible 
uniformity in legislative and regulatory regimes. Instead, there is a mosaic of rules 
ranging from blunt prohibition to more lax and permissible approaches.93 Many 
nations flatly forbid any interference with the human germline and even provide 
for criminal sanctions in selected cases.94 Others, including the United States, 
have restrictions in place that have the intended effect of making it hard to pursue 
legally clinical applications of human germline modification technologies.95 That 
said, it is vital to recognize that the American approach to the regulation of 
germline modification is very much a work in progress involving a set of complex 
institutions. In addition to the federal government and the individual state 
governments, the United States has a powerful and influential nonprofit sector 
 
 89.  Rowan Jacobsen, A Future of Genetically Engineered Children is Closer Than You’d Think, 
MOTHER JONES (Sept./Oct. 2017), http://www.motherjones.com/politics/2017/08/a-future-of-genetically-
engineered-children-is-closer-than-youd-think/ [https://perma.cc/7CH5-VHQT]. 
 90.  See Harald König, The Illusion of Control in Germline-Engineering Policy, 35 NATURE 
BIOTECH. 502, 504 (2017) (expressing skepticism that a “global ban” of human germline editing “across 
jurisdictions is feasible”).  
 91.  Cf. Margaret Foster Riley, Twenty-First Century Technologies with Twentieth Century Baggage: 
FDA in the Twenty-First Century: FDA Regulation of Regenerative Medicine, in THE CHALLENGES OF 
REGULATING DRUGS AND NEW TECHNOLOGIES 455 (Holly Fernandez Lynch & I. Glenn Cohen eds., 
2015) (exploring the challenges of regulating biomedical innovation given that the primary U.S. 
regulator, the FDA, “must regulate under statutes that are decidedly mid-twentieth century”); R. Isasi, 
E. Kleiderman & B.M. Knoppers, Editing Policy to Fit the Genome? Framing Genome Editing Policy 
Requires Setting Thresholds of Acceptability, 351 SCIENCE 337, 337 (2016) (“Balancing therapeutic 
prospects brought by scientific advances with regulation to address highly contested socioethical issues is 
the ultimate challenge in dealing with disruptive science.”). 
 92.  E.g., Bertha Maria Knoppers et al., Human Gene Editing: Revisiting Canadian Policy, 2 NPJ 
REGENERATIVE MED. 3 (2017); NAT’L ACADS. SCIS., ENG’G & MED., COMM. ON SCI., TECH., & L. 
POL’Y & GLOBAL AFFS., INT’L SUMMIT ON HUMAN GENE EDITING: A GLOBAL DISCUSSION, 
MEETING IN BRIEF (Steven Olson ed., Dec. 2015), https://www.ncbi.nlm.nih.gov/books/ 
NBK343652/pdf/Bookshelf_NBK343652.pdf [https://perma.cc/6C9P-ZENN] (summarizing discussions 
from an international summit).  
 93.  See Isasi et al., supra note 91, at 337 (emphasizing that “defining the contours and diversity of 
national policy frameworks governing the human germline is difficult”). See also R. Alta Charo, The 
Legal and Regulatory Context for Human Gene Editing, 32 ISSUES SCI. & TECH., Spring 2016, at 39 
(discussing regulatory options and enforcement mechanisms).  
 94.  Isasi et al., supra note 91, at 337.  
 95.  See I. Glenn Cohen & Eli Y. Adashi, The FDA is Prohibited from Going Germline, 353 SCIENCE 
545 (2016); König, supra note 90, at 504.  
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that plays an important role in biomedical innovation. This nonprofit sector 
includes leading research universities as well as the nongovernmental 
organizations that helped to organize the Asilomar moratorium on recombinant 
DNA research in the 1970s96 and those that more recently crafted guidelines for 
stem cell research on human embryos.97 There are also a number of professional 
associations that take an active interest in human germline modification.98 
Interacting with governmental and nonprofit entities are profit-seeking firms, 
most prominently major pharmaceutical corporations. 
The ramifications of CRISPR and other potential low cost and easy to use 
germline editing techniques are only starting to become evident. Even at this 
early date, however, there are two important observations to be made. The first 
concerns the role of markets in the development, dissemination and—perhaps 
ultimately—public acceptance of these path-breaking technologies. Calls for 
extensive public deliberation about the acceptability of human germline 
modification often assume that such deliberations must necessarily precede 
consumer access.99 This needs to be rethought. It is not only through focus groups, 
voting, and political activism that individuals construct society. Decisions 
concerning whether and how to participate in markets have important moral 
components.100 Such moral considerations are particularly salient in the context 
of medical decisions. The sorts of markets that emerge or fail to materialize in 
human germline modification services will provide crucial information about the 
moral judgments that actual individuals who face hard choices make in real life. 
Put simply, efforts to draw on “a diversity of perspectives to shape morally 
contested areas of emerging science and technology”101 should pay close attention 
to market behavior, for humans communicate through deeds as well as words. 
This leads to the second point, which concerns regulation. This article argues 
that the case for drawing a bright line between somatic and heritable genome 
editing is not persuasive on either moral or practical grounds. The logical next 
step is for heritable genome editing to be added to the portfolio of the regulatory 
entities that now oversee gene therapy and are in the process of taking on somatic 
 
 96.  See supra note 31 and accompanying text.  
 97.  See Charo, supra note 93 (describing the development of these guidelines by the International 
Society for Stem Cell Research and the National Academies of Sciences, Engineering, and Medicine).  
 98.  See, e.g., Kelly E. Ormond et al., Human Germline Genome Editing: Am. Society of Human 
Genetics Position Statement, 101 AM. J. HUM. GENETICS 167, 172–73 (2017) (“At this time, given the 
nature and number of unanswered scientific, ethical, and policy questions, it is inappropriate to perform 
germline gene editing that culminates in human pregnancy.”).  
 99.  E.g., Baltimore et al., supra note 5, at 37. 
 100.  See generally NATHAN B. OMAN, THE DIGNITY OF COMMERCE: MARKETS AND THE MORAL 
FOUNDATIONS OF CONTRACT LAW (2015); MICHAEL J. TREBILCOCK, THE LIMITS OF FREEDOM OF 
CONTRACT (1993) (discussing issues of commodification, externalities, coercion, information 
imperfections, paternalism, and discrimination).  
 101.  Debra J.H. Mathews, Robin Lovell-Badge et al., A Path Through the Thicket, 527 NATURE 159, 
161 (2015) (“For decades, people have been arguing about the pros and cons of human germline 
modification . . . [y]et good models for how to enable a diversity of perspectives to shape morally 
contested areas of emerging science and technology are hard to find.”). 
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genome editing.102 That framework could, of course, be further adjusted to take 
account of any special problems of heritable genome editing. In making these 
adjustments, it is critical for regulators and others to acknowledge that the old 
model of the government—often working in conjunction with prominent 
nonprofit groups—deciding which technologies will go forward is becoming 
obsolete as “genomic moonshining” and other evasions of their authority come 
to the fore. Regulators should consider shifting their approach from one of top 
down command and control regulation to one that places more emphasis on 
encouraging the disclosure of information about developments in heritable 
genome editing and other innovative technologies. Such an approach could help 
ensure that ground breaking research and clinical application will continue to be 
carried out in the United States, which would redound to the benefit not just of 
the U.S. but likely the entire world. Regulators should also take a careful look at 
the consequences of restricting public funding for controversial research. While 
such restrictions can serve to alleviate political discord, they also have the 
potentially deleterious side effect of decreasing public transparency and 
accountability by moving activity out of sight of democratically responsive 
entities. 
V 
CONCLUSION 
Long a staple of dystopian fiction, human germline modification may well be 
on the cusp of becoming a reality. Although to date this news has elicited more 
apprehension than celebration, there are good reasons for this to change. History 
shows that biomedical technologies with the capacity to improve the lives of 
future generations tend to win public acceptance. In addition, human germline 
modification has the potential to appeal to Americans of all political persuasions. 
Pro-choice advocates may appreciate the expansion of reproductive options, 
while those who identify as pro-life may see human germline modification as a 
vast improvement over current practices such as preimplantation genetic 
diagnosis. That is because a chief goal of human germline modification is to fix 
embryos in order to enable them to develop into healthy individuals, not to 
identify and discard the less desirable ones. In a sense, then, heritable human 
genome editing can be thought of as the ultimate pro-life technology. 
As with any technological advance, nightmare scenarios are easy to conjure 
up. No doubt human germline editing could prove highly destructive in the wrong 
hands. But the prospect of misuse is insufficient reason to draw back from 
knowledge that could greatly enhance the quality of human life by reducing or 
even eradicating diseases that have to date defeated medical science. 
****** 
 
 
 102.  See NAT’L ACADS. SCIS., ENG’G & MED., supra note 5, at 34–57 (summarizing gene therapy 
regulation in the United States).  
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In thinking about how to go forward with modifications to the human 
germline, today’s decision makers can take inspiration from the pioneers of 
aviation. Human flight was unprecedented and in some ways dangerous, yet 
humans had long envisioned doing it. And just as many works in our popular 
culture—Aldous Huxley’s 1932 novel Brave New World and the 1997 film 
Gattaca, to name but two—warn of the dangers of genetic technologies, aviators 
had the ancient myth of Daedalus and Icarus, the father and son pair who 
ventured to fly with homemade wings made of wax and bird feathers. Icarus flew 
too close to the sun and plunged into the sea when the sun’s heat melted the wax 
that held his wings together. Yet the lesson twentieth century innovators took 
from Icarus’ fate was not to stay on the ground but to soar toward the future. We 
can do the same. 
 
